OncoMethylome to test its biomarkers on Abbott's samples
Liege, Belgium-based OncoMethylome Sciences has entered into a pharmacogenomic service collaboration with US health care major Abbott Laboratories. Under the terms of their accord, the former will assist the latter in profiling tumors. Specifically, OncoMethylome will be testing its DNA methylation biomarkers on Abbott's biological samples.
"We are very pleased to add this collaboration to existing similar agreements and to use our high-throughput methylation platform to efficiently test our methylation biomarkers on biological samples provided by Abbott," commented Jim DiGuiseppi, chief technology officer of OncoMethylome. Financial details of the agreement were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze